Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset.

Frans Gorus, Eric Balti Vounsia, Ilse Vermeulen, Simke Demeester, Annelien Van Dalem, Olivier Costa, H. Dorchy, S. Tenoutasse, T. Mouraux, C. De Block, Pieter Gillard, Katelijn Decochez, J. Wenzlau, J. Hutton, Daniel Pipeleers, Ilse Weets, Belgian Diabetes Registry

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)

Abstract

In first-degree relatives of type 1 diabetic patients, we investigated whether diabetes risk assessment solely based on insulinoma antigen 2 (IA-2) and zinc transporter 8 (ZnT8) antibody status (IA-2A, respectively, ZnT8A) is as effective as screening for three or four autoantibodies [antibodies against insulin (IAA), glutamate decarboxylase 65?kDa (GAD) glutamate decarboxylase autoantibodies (GADA) and IA-2A with or without ZnT8A] in identifying children, adolescents and adults who progress rapidly to diabetes (within 5 years). Antibodies were determined by radiobinding assays during follow-up of 6444 siblings and offspring aged 0-39 years at inclusion and recruited consecutively by the Belgian Diabetes Registry. We identified 394 persistently IAA(+) , GADA(+) , IA-2A(+) and/or ZnT8A(+) relatives (6·1%). After a median follow-up time of 52 months, 132 relatives developed type 1 diabetes. In each age category tested (0-9, 10-19 and 20-39 years) progression to diabetes was significantly quicker in the presence of IA-2A and/or ZnT8A than in their joint absence (P?
Original languageEnglish
Pages (from-to)82-90
Number of pages9
JournalClin Exp Immunol
Volume171
Publication statusPublished - 2013

Keywords

  • IA-2 antibodies, prediction, prevention
  • type 1 diabetes
  • zinc transporter 8 antibodies

Fingerprint

Dive into the research topics of 'Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective strategy to identify relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset.'. Together they form a unique fingerprint.

Cite this